About us
The management of Inthera Bioscience AG has more that 100 years of combined experience within biotech/pharma industry. Their expertise covers the entire value chain from target discovery and validation to early drug discovery, medicinal chemistry, pre-clinical and toxicology works as well as early clinical development. Furthermore the team has substantial experience in business development, deal transactions in general and in people management.
Board of Directors
Anker Lundemose
CEO Mission Therapeutics
Mark Krul
Aglaia Oncology Funds
Karl Rothweiler
Aglaia Oncology Funds